600566.SH
济川药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 24.40
+0.04%Year over year
Reported trailing growth
- Revenue
- -17.4%
- EBITDA
- —
- EBIT
- -14.1%
- EPS
- -18.3%
- Free cash flow
- -32.8%
- Operating cash flow
- -21.3%
Forward estimates
Based on analyst estimates
- Revenue
- +29.1%
- EBITDA
- +19.1%
- EPS
- +28.1%
Three-year CAGR
- Revenue
- -11.6%
- EBITDA
- -3.4%
- EBIT
- -3.8%
- Net income
- -6.4%
- EPS
- -7.5%
- Free cash flow
- -22.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026